PET Changes in Alzheimer's Disease (AD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00094913|
Recruitment Status : Unknown
Verified July 2007 by National Institute on Aging (NIA).
Recruitment status was: Active, not recruiting
First Posted : October 29, 2004
Last Update Posted : May 27, 2009
|Condition or disease|
Previous studies indicate that the brain's glucose metabolism rate potentially may be an early indicator of damage to particular regions of the brain caused by AD, including loss of neurons, synapses, and other changes. Many of these changes are reported among patients with mild cognitive impairment (MCI), a group known to be at increased risk for AD.
The overall goal of this study is to use FDG-PET (2-[(18)F]fluoro-2-deoxy-d-glucose/positron-emission tomography) to determine whether metabolic abnormalities in the hippocampus predict memory and brain deterioration in middle age, and to identify the brain glucose metabolism predictors of future MCI.
Participants in the study will be grouped into 3 main groups of 35 each, including young individuals (20-40 years of age), 41-90 year-old normal, and MCI individuals with or without risk for memory decline. Participants will undergo baseline and 36-month follow-up exams to include comprehensive medical, neurologic, and psychiatric evalutions; lumbar puncture; a resting FDG-PET; an MRI scan; and a neuropsychological battery. A brief medical exam, full neuropsychological battery, and MRI scan will be administered at 18 months. Two subgroups (groups 4 and 5) of 15 each will be created from groups 1 and 2 at 18 months to participate in the evaluation of memory performance under acute hyperglycemia and saline challenges and effects on hippocampal formation and glucose metabolism.
|Study Type :||Observational|
|Estimated Enrollment :||105 participants|
|Official Title:||Clinical Correlates of Longitudinal PET Changes in Alzheimer's Disease (AD)|
|Study Start Date :||May 2004|
|Study Completion Date :||April 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00094913
|United States, New York|
|Center for Brain Health, Silberstein Institute, New York University|
|New York City, New York, United States, 10016|
|Principal Investigator:||Mony J. de Leon, Ed.D.||Center for Brain Health, Silberstein Institute|